2. Signaling Pathways
  3. GPCR/G Protein
  4. Prostaglandin Receptor
  5. Prostaglandin Receptor Isoform
  6. Prostaglandin Receptor Inhibitor

Prostaglandin Receptor Inhibitor

Prostaglandin Receptor Inhibitors (83):

Cat. No. Product Name Effect Purity
  • HY-403733B
    (+)-JJ-450
    		Inhibitor
    (+)-JJ-450 is a non-competitive antagonist targeting the androgen receptor (AR) that inhibits AR nuclear localization and transcriptional activity in the absence of androgen. (+)-JJ-450 is less active than (-)-JJ-450 (HY-403733A) in inhibiting prostate-specific antigen (PSA) expression in LN95 cells, possibly because (+)-JJ-450 targets the ligand binding domain (LBD) of AR. (+)-JJ-450 inhibits the transcriptional activity of AR and its splice variants (e.g., ARv7) by promoting the degradation of unliganded AR in the nucleus and reducing the binding of AR to androgen response elements (AREs). (+)-JJ-450 can be used in castration-resistant prostate cancer (CRPC) studies that are resistant to enzalutamide (MDV3100) (HY-70003).
  • HY-N0677
    Dehydroandrographolide succinate
    		Inhibitor 99.88%
    Dehydroandrographolide succinate can be extracted from herbal medicine Andrographis paniculata (Burm f) Nees, is widely used in research for viral pneumonia and viral upper respiratory tract infections because of its immunostimulatory, anti-infective and anti-inflammatory effect. Dehydroandrographolide succinate exerts antithrombotic effect. Dehydroandrographolide succinate significantly inhibits the platelet aggregation rate (ED50 = 386.9 mg/kg) by decreasing TXB2 levels. Dehydroandrographolide succinate mitigates muscle astrophy via the Akt/GSK3β and MuRF-1 pathways.
  • HY-B1074
    Ethamsylate
    		Inhibitor 99.49%
    Ethamsylate (Etamsylate) is an orally active anti-hemorrhagic compound. Ethamsylate inhibits biosynthesis and action of prostaglandins. Ethamsylate has the potential to maintain early hemostasis as well as restores capillary resistance. Ethamsylate acts as an antiangiogenic factor, inhibiting wound healing and matrigel tubulogenesis..
  • HY-133079
    Ascorbyl tetra-2-hexyldecanoate
    		Inhibitor ≥98.0%
    Ascorbyl tetra-2-hexyldecanoate (tetra-isopalmitoyl Ascorbic acid; IPAA) is a lipophilic derivative of vitamin C (L-ascorbic acid). Ascorbyl tetra-2-hexyldecanoate (100 μM ) can prevent the decrease in viability of HaCaT keratinocytes induced by UVB, hydrogen peroxide, or tert-butyl hydroperoxide, and reduce the production of IL-1α and prostaglandin E2 (PGE2). Topical application of ascorbyl tetra-2-hexyldecanoate (1%) increases epidermal viability thickness, stratum corneum water content, and skin smoothness, and reduces skin roughness in hairless mice. Ascorbyl tetra-2-hexyldecanoate can be used to develop skin whitening agents in the beauty industry.
  • HY-15342A
    Timapiprant sodium
    		Inhibitor 99.61%
    Timapiprant sodium (OC000459 sodium) is a potent, selective, and orally active D prostanoid receptor 2 (DP2, also known as CRTH2) antagonist. Timapiprant sodium (OC000459 sodium) potently displaces [3H] PGD2 from human recombinant DP2 (Ki=13 nM), rat recombinant DP2 (Ki=3 nM), and human native DP2 (Ki=4 nM). Timapiprant sodium (OC000459 sodium) inhibits mast cell activation of Th2 lymphocytes and eosinophils.
  • HY-101813
    Laflunimus
    		Inhibitor 99.70%
    Laflunimus (HR325) is an immunosuppressive agent and an analogue of the Leflunomide-active metabolite A77 1726. Laflunimus is an orally active inhibitor of dihydroorotate dehydrogenase (DHODH). Laflunimus suppresses immunoglobulin (Ig) secretion, with IC50 values of 2.5 and 2 µM for IgM and IgG, respectively. Laflunimus also is a prostaglandin endoperoxide H synthase (PGHS) -1 and -2 inhibitor.
  • HY-130223
    11β-Prostaglandin E2
    		Inhibitor ≥99.0%
    11β-Prostaglandin E2 (11β-Dinoprostone), a Prostanoid derivative, inhibits [3H]PGE2 binding to hypothalamic membranes in the rat with a Ki of 53.3 nM.
  • HY-107795
    Benorilate
    		Inhibitor 99.85%
    Benorylate (Salipran) is the esterification product of paracetamol and acetylsalicylic acid. Benorylate has anti-inflammatory, analgesic and antipyretic properties. Benorylate could also inhibit prostaglandin (PG) synthesis.
  • HY-106067A
    Dazoxiben hydrochloride
    		Inhibitor 99.90%
    Dazoxiben hydrochloride is a potent and orally active thromboxane (TX) synthase inhibitor.
  • HY-106080A
    Furegrelate sodium
    		Inhibitor 99.82%
    Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent.
  • HY-114564
    Satigrel
    		Inhibitor 99.85%
    Satigrel (E5510) is a potent inhibitor of platelet aggregation. Satigrel inhibits collagen- and arachidonic acid-induced platelet aggregation through preventing thromboxane A2 synthesis by selective inhibition of the target enzyme, PGHS1, which exists in platelets. Satigrel inhibits PGHS1 (IC50: 0.081 μM) and PGHS2 (IC50: 5.9 μM). Satigrel is against Type III PDE, Type V and Type II (IC50: 15.7 μM, 39.8 μM and 62.4 μM, respectively).
  • HY-17477
    Guacetisal
    		Inhibitor 99.95%
    Guacetisal is obtained from the esterification of acetylsalicylic acid with guaiacol which has the potential for chronic bronchitis treatment extracted from patent CN 106866420 A.
  • HY-138665
    HHS-0701
    		Inhibitor 98.90%
    HHS-0701, a sulfur-triazole exchange (SuTEx) ligand, is a potent tyrosine-reactive prostaglandin reductase 2 (PTGR2) inhibitor. HHS-0701 blocks PTGR2 metabolism of the lipid substrate 15-Keto-PGE2.
  • HY-101438
    Darbufelone
    		Inhibitor 99.49%
    Darbufelone is a dual inhibitor of cellular PGF2α and LTB4 production. Darbufelone potently inhibits PGHS-2 (IC50= 0.19 μM) but is much less potent with PGHS-1 (IC50=20 μM).
  • HY-N10225
    Thielavin A
    		Inhibitor 98.5%
    Thielavin A is an inhibitor of prostaglandin biosynthesis produced by Thielavia terricola. Thielavin A specifically inhibits the conversion of arachidonic acid into prostaglandin H2. Thielavin A has no anti-inflammatory activity on intravenous injection or on oral administration.
  • HY-W009706
    Alclofenac
    		Inhibitor 99.44%
    Alclofenac (Allopydin) is a non-steroidal anti-inflammatory agent (NSAID). Alclofenac is a prostaglandin H2 synthase inhibitor. Alclofenac can be used for rheumatoid arthritis, degenerative joint disease and ankylosing spondylitis research.
  • HY-Z7721
    (Rac)-Beraprost sodium
    		Inhibitor
    (Rac)-Beraprost ((Rac)-ML 1129) sodium is a racemic isomer of Beraprost sodium (HY-13569A). Beraprost sodium is an orally active prostacyclin analog that inhibits the release of Ca2+ from intracellular storage sites by binding to prostacyclin membrane receptors (Prostaglandin Receptor), leading to relaxation of smooth muscle cells and vasodilation. Beraprost sodium has vasodilatory, antiplatelet, and cytoprotective effects, making it promising for research in the field of cardiovascular diseases, such as thromboangiitis obliterans and atherosclerosis.
  • HY-124192
    Amogastrin
    		Inhibitor
    Amogastrin is a tetrapeptide that stimulates gastric extraction of 99mTc pertechnetate. Amogastrin can be used for the research of gastric mucosal disease imaging. Amogastrin stimulates the production of prostate hormones.
  • HY-108308
    Ibuprofen guaiacol ester
    		Inhibitor 98.49%
    Ibuprofen guaiacol ester (AF 2259; Metoxibutropate) is a potent and orally active prostaglandin synthesis inhibitor. Ibuprofen guaiacol ester has the potential for the research of edema and fever.
  • HY-17350
    Anitrazafen
    		Inhibitor
    Anitrazafen is a topically effective antiinflammatory agent.